HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Tan Sheet

Executive Summary

FDA issues guidance on splitting tablets

You may also be interested in...



In Brief

Chaffetz will not challenge Hatch

NDI Guidance Is “Radical Departure” From DSHEA; More Comment Time Needed – Attorney

The new dietary ingredient notification draft guidance is a “radical departure” from current industry practice and FDA should extend the comment period on the draft to one year, an attorney says.

Germany’s OTC Market In 2023: Cough, Cold & Flu and Probiotics Drove Steady Growth

German consumers are “generally willing to accept price increases from OTC manufacturers” when it comes to core categories like cough, cold & flu, finds Sempora, and are increasingly willing to shell out for trending gut health products like probiotics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel